CD8 T cell memory in B cell-deficient mice by unknown
CD8 T  Cell Memory in B  Cell-deficient Mice 
By Mary S. Asano* and Raft Ahmed* 
From the *Department of Microbiology and Immunology, University of California at Los Angeles 
School of Medicine, Los Angeles, California 90024; and *Emory Vaccine Center and Department of 
Microbiology and Immunology, Emory University School of Medicine,  Atlanta, Georgia 30322 
Summary 
Antigen  presentation by B  cells  and persistence  of antigen-antibody complexes on follicular 
dendritic cells (FDC) have been implicated in sustaining T  cell memory. In this study we have 
examined the role of B  cells and antibody in the generation and maintenance of CD8 + cyto- 
toxic  T  lymphocyte (CTL)  memory. To  address  this  issue  we compared CTL responses  to 
lymphocytic choriomeningitis virus  (LCMV)  in normal  (+/+)  versus B  cell-deficient mice. 
The CTL response to acute LCMV  infection can be broken down into three distinct phases: 
(a)  the  initial  phase  (days  3-8  after infection)  of antigen-driven  expansion  of virus-specific 
CD8 § T  cells and the development ofeffector CTL (i.e., direct ex vivo killers);  (b) a phase of 
death (between days 10 and 30 after infection) during which >95% of the virus-specific CTL 
die and the direct effector activity subsides; and (c) the phase of long-term memory (after day 
30) that is characterized by a stable pool of memory CTL that persist for the life span of the an- 
imal. The role of B  cells in each of these three phases of the CTL response was analyzed. We 
found that B  cells  were not required for the expansion and activation of virus-specific CTL. 
The kinetics and magnitude of the effector CTL response, as measured by direct killing of in- 
fected targets by ex vivo isolated splenocytes, was identical in B cell-deficient and +/+  mice. 
Also,  the expansion of CD8 + T  cells was not affected by the absence of B  cells  and/or anti- 
body; in both groups of mice there was an "~10,000-fold increase in the number of LCMV- 
specific CTL and a greater than  10-fold increase in  the  total number of activated (CD44hi) 
CD8 + T  cells  during the first week after virus infection.  Although  no differences were seen 
during the  "expansion" phase, we found that the  "death" phase was more pronounced in B 
cell-deficient mice.  However, this  increased cell death was not selective for LCMV-specific 
CTL, and during this period the total number of CD8 + T  cells also dropped substantially more 
in B cell-deficient mice. As a result of this, the absolute numbers ofLCMV-specific CTL were 
lower in B  cell-deficient mice but the frequencies were comparable in both groups of mice. 
More significantly, the memory phase of the CTL response was not affected by the absence of 
B cells and a stable number ofLCMV-specific CTL persisted in B cell-deficient mice for up to 
6  too.  Upon reinfection,  B  cell-deficient mice that had  resolved an acute  LCMV infection 
were able  to  make accelerated  CTL responses in vivo and  eliminated virus more efficiently 
than naive B cell-deficient mice. Thus, CTL memory, as assessed by frequency of virus-specific 
CTL or protective immunity, does not decline in the absence of B cells. Taken together, these 
results show that neither B  cells nor antigen-antibody complexes are essential for the mainte- 
nance of CD8 + CTL memory. 
C 
D8  CTL constitute an important defense mechanism 
against intracellular pathogens (1-4). Both effector and 
memory CTL play critical but distinct roles in antiviral im- 
munity. Effector CTL control infection by killing infected 
cells and secreting cytokines such as IFN-~/(5-7). Memory 
CTL play an important role in protective immunity (1-4, 
8-11);  they do not prevent infection per se,  but limit the 
severity  of  infection/disease  by  making  accelerated  re- 
sponses upon reexposllre (8-11). Memory CTL are qualita- 
tively distinct from naive CTL and express higher levels of 
adhesion  molecules  (8-11).  Upon  reencounter  with  spe- 
cific antigen, memory CTL proliferate rapidly, differentiate 
into effector cells, get to the site of infection, and eliminate 
infected cells. 
Long-term CTL memory is seen in many different anti- 
genic systems and under both natural and experimental sit- 
uations (8-11).  For example, mice that have undergone an 
acute infection with influenza virus, Sendai virus, or lym- 
phocytic choriomeningitis virus  (LCMV) 1 exhibit lifelong 
IAbbreviations used in this paper: FDC, follicular dendritic cell; LCMV, 
lymphocytic  choriomeningitis virus. 
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long-term CTL memory in humans,  by isolating vaccinia 
virus-specific  CTL  from  individuals  vaccinated  >30  yr 
earlier (17). Prolonged CTL memory is also seen in several 
"noninfectious"  antigenic  systems  (i.e.,  H-Y,  ovalbumin), 
and also after immunization with peptides (1,  8-i 1). 
A  question  of fundamental importance is how this long 
lasting CD8 + T  cell memory is maintained. The more con- 
ventional  model  has  been  that  long-term  memory is  de- 
pendent  on  persistent  antigenic  stimulation  (8,  14,  18). 
Several  recent  studies,  however,  have  provided  evidence 
that the original priming antigen is not essential for the main- 
tenance  of CD8 +  T  cell memory  (13,  15,  16,  19).  How- 
ever, this issue still remains controversial and one of the ar- 
guments  is  that  antigen-antibody  complexes persisting  on 
follicular dendritic cells  (FDC) provide a stimulus for mem- 
ory T cells (8). It is well established that FDC can trap antigen 
in the form of antigen-antibody complexes and retain it on 
their cell surface for long periods of time  (8,  20, 21). Since 
FDC are inefficient in antigen processing,  it has been pos- 
tulated that B  cells pick up this trapped antigen and present 
it to T  cells,  thereby sustaining long-term memory (8).  Al- 
though  this  mode  of antigen  loading  favors  presentation 
through MHC class II molecules, there are now several ex- 
amples  of exogenous  antigens  being  processed  and  pre- 
sented  by MHC  class  I  molecules  (22,  23).  Thus,  antigen 
depots on FDC could play a role in sustaining CD8 + T  cell 
memory. The availability of B  cell-deficient mice  (p,  MT/ 
pLMT)  (24)  now allows us to formally test this hypothesis 
and examine the role of B ceils and antigen-antibody com- 
plexes  in  the  generation  and  persistence  of CD8 §  T  cell 
memory.  In this  study  we  have  analyzed LCMV-specific 
CTL  responses  in  B  cell-deficient  mice  and  compared 
them with responses seen in  +/+  mice. 
Materials and Methods 
Mice.  IxMT/p~MT  mice were made by targeted disruption of 
one of  the membrane exons of  the IgM H chain (24). txMT (-/-) 
mice back-crossed on a C57BL/6 background were kindly pro- 
vided by Dr.  Herbert Virgin (Washington University School of 
Medicine,  St.  Louis,  MO)  or purchased from The Jackson Lab- 
oratory (C57BL/6-Igh; Bar Harbor, ME). Mice were then bred and 
maintained  at the University of California,  Los Angeles. C57BL/6 
(+/+)  mice were purchased from The Jackson Laboratory.  The 
C57BL/6 LCMV carrier  colony was established and bred at  the 
University of California,  Los Angeles as previously described  (25). 
Virus.  The Armstrong CA 1371 strain of LCMV was used in 
these studies for infection of mice (26). Spleen variant clones  13 
or 28b were used in rechallenge  experiments.  These variants were 
isolated from the spleens of adult BALB/c carrier mice infected at 
birth  with  the Armstrong CA 1371  strain  (26,  27).  All LCMV 
stocks used in this study were triple plaque purified on Vero cells, 
and the stocks were grown in BHK-21 cells. Virus stocks  at the 
passage one or two level were used in all experiments.  Infectious 
virus was quantitated by plaque assay (26). 
Antibodies.  The  numbers  of CD8  +  and  CD4 +  cells in  the 
spleen, blood, and LN were determined by staining with specific 
mAbs followed by analysis on a FACScan  |  flow cytometer (Bec- 
ton Dickinson &  Co., San Jose,  CA). The following antibodies 
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were  used:  R-phycoerythrin-conjugated  rat  anti-mouse  CD4 
(RM4-5),  biotin-conjugated  rat  anti-mouse  CD8a  (53-6.7), 
FITC-conjugated rat anti-mouse CD44 (IM7) from PharMingen 
(San Diego, CA), and streptavidin  r-phycoerythrin from Caltag 
Laboratories  (South San Francisco,  CA). All antibodies  were used 
at concentrations recommended by the manufacturers. 
Cytotoxicity Assay.  LCMV-specific CTL activity of spleen and 
LN cells (pooled a,~llary, mesenteric, and inguinal) was measured by 
a standard 6-h SlCr-release assay on uninfected  and LCMV-infected 
MC57 (H-2  b) targets (26). To determine CTL recognition of the 
three major H-2b-restricted LCMV epitopes,  MC57 target cells 
were coated with selected  LCMV peptides  at a concentration of 
2 p~g/ml for 1 h at 37~  Effector cells were then added to pre- 
pared targets. Peptides  were a gift from Cytel (San Diego, CA). 
In  kitro Depletion of CD8 + Cells.  Spleen cells were treated with 
anti-Ly 2.2  mAb  (anti-CDS)  purchased  in  the  form of ascites 
fluid  plus rabbit complement (low tox M; both from Cedarlane 
Laboratories  Ltd., Hornby, ON, Canada)  or complement alone. 
Antibody and complement were used at concentrations specified 
by the manufacturer. After depletion, cells were enumerated and 
used as effectors in the cytotoxicity assays. 
Antibody Titrations.  LCMV-specific antibody in serum was mea- 
sured by a solid-phase  ELISA as previously described  (26). 
Determination qf the LCMV-spedfic CTLp Frequency.  Spleen  cells 
from LCMV-immunized mice were cultured in graded  doses in 
96-well flat bottom plates (12 wells per dose). 8 ￿  10  s syngeneic 
feeder spleen  cells from uninfected mice and 2  ￿  10  s syngeneic 
stimulator  spleen  cells from LCMV carrier  mice were irradiated 
(1,200  rad)  and added to each well.  Recombinant human IL-2 
from Escherichia coli (specific activity  18  ￿  106 IU mg  -~  (Cetus 
Corp.,  Emeryville,  CA)  was  added  at  a final  concentration  of 
50 U  m1-1. After 8 d, the contents from each well were split to 
test CTL activity  against LCMV-infected and Uninfected  MC57 
targets in a 6-h SlCr-release assay. 
Results 
Kinetics of the CD8 + CTL Effector Response in B  Ceii-deft- 
cient Mice.  To determine whether B  cells  play a role dur- 
ing induction of the primary CTL response, we compared 
the kinetics of the CTL effector response in B cell-deficient 
and  age-matched  C57BL/6  (+/+)  mice  during  an  acute 
LCMV.  Mice  were  infected  with  2  ￿  10  s  i.p.  PFU  of 
LCMV Armstrong,  and  direct  ex vivo cytotoxicity in the 
spleens  was  measured  at  various  times  after  infection 
(Table  1). 
On day 3  of infection, the majority of the cytotoxic re- 
sponse  in  the  spleens  was  nonspecific,  with  lysis  of both 
LCMV-infected  and  uninfected  target  cells.  By  day  5, 
LCMV-specific CTL activity was detectable  in both the B 
cell-deficient  and  +/+  mice.  Although  there  was  still 
some lysis of uninfected target cells, there was less than that 
seen at day 3. Previous work has shown that the early non- 
specific cytotoxic activity after LCMV infection is  due  to 
natural killer cells  (28). 
The magnitude of the  CTL response increased dramati- 
cally by day 8  of infection, when spleen cells  from both B 
cell-deficient  and  +/+  mice  demonstrated  high  specific 
killing  of LCMV-infected targets.  Results  from two sepa- 
rate experiments showed that the magnitude of the primary 
CTL effector response in the spleens of -/-  mice was corn- 
B Cell-deficient Mice Table 1.  B  Cell-deficient Mice Generate a Pn'mary LCMV-specific CTL Effector Response* 
Percent specific 51Cr-release from MC57(H-2  b) targets at indicated E/T ratio 
LCMV-specific CTL in the spleen  LCMV-specific CTL in LN 
LCMV Infected  Uninfected  LCMV infected  Uninfected 
Mouse  Days after 
genotype  infection  50:1  16.6:1  5.5:1  50:1  16.6:1  5.5:1  50:1  16.6:1  5.5:1  50:1  16.6:1  5.5:1 
-  /  -  3  3 l  12  4  19  7  1  ND  ND  ND  ND  ND  ND 
+/+  3  11  9  10  18  15  13  ND  ND  ND  ND  ND  ND 
-/-  5  24  14  5  10  5  2  28  12  5  4  1  1 
+/+  5  22  10  4  6  2  1  14  16  2  7  2  0 
-/-  8  68  54  36  4  1  0  31  12  2  I  0  0 
+/+  8  64  48  20  0  0  0  42  29  13  0  0  0 
-/-  16  42  25  12  0  1  0  3  0  0  2  2  3 
+/+  16  35  14  7  0  0  0  3  1  0  0  0  0 
*6-8-wk-old mice were infected i.p. with 2 ￿  105 PFU of LCMV Armstrong. Direct ex vivo LCMV-specific CTL activity was measured by a 6-h 
S~Cr_release assay at the indicted days after infection. Data represent the average of two to four mice per group. 
parable to that seen in +/+  mice. In B  cell-deficient mice, 
depletion of CD8 +  T  ceils using a  mAb and complement 
before  the  cytotoxicity assay abrogated  90%  of the  mea- 
sured  CTL  response  at  day 8,  demonstrating that  as with 
+/+  mice, primed CD8 + T  cells were responsible for the 
direct ex vivo CTL response seen (data not shown). By day 
16, CTL activity showed over a threefold drop in both the 
B  cell-deficient and the +/+  mice; and by day 30 after in- 
fection, direct ex vivo cytotoxic responses had come down 
to baseline (data not shown). LN cells from B  ceil-deficient 
mice also showed direct ex vivo cytotoxicity, although re- 
sponses were generally lower than that seen in the spleens. 
LCMV-specific responses were detected at days 5 and 8 af- 
ter infection,  and had  come  down  to  baseline by day  16. 
Similar results were seen in  +/+  mice. These experiments 
demonstrated  that  the  kinetics and  magnitude  of the  pri- 
mary CTL effector response in B  cell-deficient mice is sim- 
ilar to + / +  mice. 
Epitope Repertoire in B  Cell-deficient Mice.  To  determine 
whether CTL from B  cell-deficient mice recognize the same 
LCMV epitopes as those of +/+  mice, direct ex vivo cy- 
totoxicity was measured using targets coated with peptides 
from three of the major LCMV epitopes. In H-2 b mice, the 
dominant  LCMV  CTL  epitopes are  nucleoprotein  amino 
acids  396-404,  and  glycoprotein  amino  acids  33-42  and 
278-286 (29-31). As seen in Table 2, spleen cells from B cell- 
deficient  mice  infected  8  d  previously were  able  to  lyse 
peptide-coated targets in an identical manner to spleen cells 
from  +/+  mice. LN cells from B  cell-deficient mice also 
showed a similar pattern of killing (data not shown). Thus, 
LCMV-specific CTL primed in the absence orB  cells rec- 
ognize the same CTL epitopes as those primed in the +/+ 
environment. 
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CD8 + T  Cell Expansion and Activation.  For  further  as- 
sessment of the  CD8 +  T  cell response in B  cell-deficient 
mice,  we  quantitated  CD8  expansion and  activation after 
LCMV infection. Six infected and six uninfected mice were 
evaluated per  group.  At baseline,  uninfected  B  ceil-defi- 
cient mice had significantly smaller spleens than uninfected, 
age-matched +/+  mice. Spleens from  -/-  mice were on 
average sixfold smaller than  spleens of +/+  mice,  and in 
addition to lacking B  ceils, also contained fewer CD4 + and 
CD8 + T  cells. In -/-  mice, the average number ofCD4 + 
T  ceils was 5.5  ￿  10  6  -~  1.2  X  10  6 SD versus 1.8  ￿  10  7 ---+ 
4.6  ￿  106  SD  in  +/+  mice.  The  average  number  of 
CD8 § T  cells was 4.0 X  10  6 +  1.2 ￿  10  6 SD in --/-  mice 
versus 9.7  X  106 __+ 3.2 X  10  6 SD in +/+  mice. Despite the 
difference in total numbers, CD8 § spleen cells from B  cell- 
deficient and +/+  mice showed a similar degree of expan- 
sion in response to LCMV infection. B  cell-deficient mice 
had a  10-fold increase in the number of CD8 § spleen cells 
by day 8, versus a ninefold increase in +/+  mice. 
To  assess CD8  activation,  cells were  double stained for 
CD8  and  CD44,  an  adhesion molecule whose  expression 
goes up in activated T  ceils (8-11). Representative FACS  | 
analyses of the spleen and blood from B  cell-deficient and 
+/+  mice are shown in Fig.  1.  Comparison of uninfected 
and day 8-infected mice illustrates the tremendous increase 
in the overall percentage of CD8 §  cells and the percentage 
of CD8 §  cells expressing the  activated  (CD44hi)  pheno- 
type. The total number of activated CD8 + cells in the spleens 
increased 20-fold in  -/-  mice and 10-fold in  +/+  mice. 
Whereas the number of activated CD8 +  ceils increased dra- 
matically after infection, the number of resting CD8 + ceils 
remained  relatively unchanged  in  both  groups.  This  re- 
sulted in a large increase in the ratio of activated versus rest- Table 2.  CTL fiom B Cell-defident Mice Recognize the Three Major CTL Epitopes of LCMV 
LCMV-specific CTL in the spleen 
Percent specific S~Cr-release from peptide-coated* MC57 (H-2  ~) targets at indicated E/T ratio 
NP 396-404  GP 33-42  GP 276-286  Uninfected 
Mouse 
genotype*  50:1  16.6:1  5.5:1  50:1  16.6:1  5.5:1  50:1  16.6:1  5.5:1  50:1  16.6:1  5.5:1 
-/-  50  33  20  36  35  18  10  4  1  0  0  0 
+/+  42  21  8  38  23  18  15  6  0  0  0  0 
*6-8-wk-old mice were infected i.p. with 2 ￿  10  s PFU of LCMV Armstrong.  Direct ex vivo LCMV-specific CTL activity was measured  8 d later. 
Data represent the average of two mice for each group. 
*MC57 (H-2  ~) targets were coated with peptides  representing the three major LCMV epitopes recognized by CTL from mice of the H-2 ~ back- 
ground. LCMV nucleoportein amino acids 396-404 and glycoprotein amino acids 33-42 and 278-286 were used. 
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Figure 1.  Expansion and activation ofCD8 + T cells in B cell-deficient 
mice. Representative  FACS  |  analysis of spleen and blood cells from unin- 
fected and  day 8-infected B cell-deficient and  +/+  mice.  B cell-deft- 
ing  CD8 +  T  cells  (Fig.  2).  In  uninfected  B  cell-deficient 
mice,  the  ratio  of activated  to  resting  CD8 +  spleen  cells 
ranged from 0.5 to 0.6. By day 8 after infection, the ratio of 
activated to resting CD8 +  cells had increased an average of 
20-fold, and now ranged from 5  to  17.  In uninfected  +/+ 
mice,  the  ratio  of activated  to  resting  CD8 +  spleen  ceils 
ranged  from  0.6  to  1.2.  After infection,  the  ratio  ranged 
from 9  to 25, a  15-fold average increase. 
These  results  demonstrated  that  CD8 +  cells  in  B  cell- 
deficient  and  +/+  mice show  a  similar  degree  of expan- 
sion and activation after LCMV  infection, with a 9-10-fold 
increase in CD8  numbers  and a  15-20-fold increase  in the 
ratio of activated to resting CD8 + cells. 
B  Cell-deficient  Mice  Clear  an  Acute  LCMV  Infection. 
To  evaluate  the  kinetics  of viral clearance  in  B  cell-defi- 
cient mice, we measured levels of infectious virus in various 
tissues  on  days  5  and  8  after  LCMV  Armstrong  infection 
(Table 3).  On  day 5  of infection, infectious virus could be 
found in the serum,  liver, lung,  and spleen of both B  cell- 
deficient  and  +/+  mice.  Levels  of infectious  virus  were 
slightly higher in the B  cell-deficient mice at day 5, but by 
day 8, there was no detectable infectious virus in the serum, 
brain,  kidney,  liver,  lung,  or spleens  of both  the  B  cell- 
deficient  and  +/+  mice.  The  difference  in  viral  titers  at 
day 5 may be related to either the lack of B  cells and/or an- 
tibody,  or to  the  lower number  of CD8 +  cells in  B  cell- 
deficient  mice.  Overall,  however,  the  kinetics  of  viral 
clearance in the B  cell-deficient mice follows a similar pat- 
tern to that seen in  +/+  mice. 
cient and  +/+  mice showed  a significant increase in the percentage  of 
CD8  + cells in the spleen and blood after infection,  with a tremendous 
shift in the percentage  of cells expressing the activated CD44hi pheno- 
type. X- and Y-axes are in logm fluorescence. Numbers indicate percent- 
age of cells in each quadrant.  (The total number of CD8  + T ceils in the 
spleens of uninfected  -/-  mice was  about  twofold less than  in  +/+ 
mice,  although  CD8 percentages  were higher in  -/-  mice because of 
the absence of B cells). 
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Figure 2.  CD8 § T  cells in B cell-deficient mice are activated in re- 
sponse to an acute LCMV infection. Spleen cells  from six uninfected B cell- 
deficient and 6 B cell-deficient mice infected 8 d previously with LCMV 
Armstrong were double stained for CD8 and CD44.  Total numbers of 
activated (CD44hl) and resting (CD441o) CD8 + T cells in the spleens of 
individual mice are shown. In uninfected mice, the ratio of activated to 
resting CD8 + cells was 0.4-0.6. By day 8 after infection, there was a large 
shift in this ratio (ranging from 5 to 17), due to a greater than 20-fold in- 
crease in the number of activated CD8 + T cells. 
Maintenance of CD8 + CTL Memory.  To  determine whether 
B  cells or antibody are needed for maintaining CTL mem- 
ory, we quantitated the number of LCMV-specific memory 
CTL in the spleens of -/-  and + / +  mice at various times 
after infection. The results of these limiting dilution analy- 
ses are shown in Fig. 3 A. In both B  cell-deficient and +/+ 
mice, the CTLp frequency per spleen cell peaked at 1/30 at 
8 d after infection. By day 16, the CTLp frequency began to 
fall in both groups. From days 35-170, CTLp frequencies in 
B  cell-deficient mice ranged from 1/110 to 1/4,150. In +/+ 
mice,  CTLp  frequencies  ranged  from  1/120  to  1/1,180. 
This variation, however, showed no specific trend over time, 
illustrating that in B  cell-deficient and +/+  mice, the CTLp 
frequencies are being maintained at relatively the same rate. 
Table  3.  B Cell-deficient Mice Are Able to Control an Acute 
LCMV Infection 
Mouse  Days after 
genotype*  infection 
LCMV titer 
(Log~0 PFU/ml of serum or gram of tissue) 
Serum  Brain  Kidney Liver  Lung  Spleen 
-/-  5  3.2  ND  ND  5.2  4.3  2.8 
+/+  5  2.2  ND  ND  4.5  4.0  2.5 
-/-  8  <l.7  <2.7  <3.0  <2.7  <3.0  <2.3 
+/+  8  <1.7  <2.7  <3.0  <2.7  <3.0  <2.3 
*6-8-wk-old mice were infected i.p. with 2  X  10  s PFU of the Arm- 
strong strain of  LCMV, and virus titers were checked 5 and 8 d after in- 
fection. Data represent the average of  four -/-  mice and two +/+ mice 
for each time point. 
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At day 8  after infection, the total number  of CTLp per 
spleen was approximately threefold higher in + / +  mice com- 
pared with B  cell-deficient mice. By day 16, both groups 
showed a rapid decrease in CTLp numbers and then a more 
gradual decline until day 50. During this time, when apop- 
totic T  cell death occurred, B  cell-deficient mice showed a 
greater  decline  in  CTLp  numbers  compared  with  +/+ 
mice. B  cell--deficient mice had over a 60-fold decrease in 
LCMV-specific  CTLp  cells compared with  a  13-fold de- 
crease in  +/+  mice.  From day 80  and  beyond,  the  total 
number of CTLp  cells remained lower in the B  cell-defi- 
cient mice compared with  +/+  mice. Although there was 
some variation in the total CTLp numbers during this time, 
both groups then maintained a relatively stable population 
ofLCMV-specific CTL for up to 6 mo after infection. 
Fig. 3 B shows the number of activated CD8 + spleen cells 
(CD44hi) in B  cell-deficient and +/+  mice from days 3 to 
170  after infection.  Uninfected  B  cell-deficient mice had 
approximately half the number of CD8 + T  cells as the un- 
infected  +/+  mice  (with both  CD44hi  and CD441o  cells 
being two- to threefold lower). By day 8  after LCMV in- 
fection, the number of activated CD8 + cells in both  -/- 
and +/+  mice were nearly equal (less than 1.5-fold differ- 
ence).  Numbers  of activated CD8+cells began to decrease 
thereafter,  with  -/-  mice  showing  a  greater drop  com- 
pared with  +/+  mice. From days 8 to 50, B  cell-deficient 
mice had  a  23-fold drop in activated CD8 +  cells versus a 
sevenfold  drop  in  +/+  mice.  Although  B  cell-deficient 
mice showed greater cell loss during the "death" phase, the 
number of activated CD8 + cells stabilized from day 50 and 
beyond (in the maintenance phase). Numbers  of activated 
CD8 +  cells then remained two- to fivefold lower in B  cell- 
deficient mice compared with  +/+  mice, returning close 
to preinfection levels for each group. Fig. 3  C  shows that in 
contrast to the changes seen in the CD44hi population, the 
number  of CD8 +  CD441o  cells remained relatively stable 
throughout  the  time period studied.  At day 8  after infec- 
tion,  there  was  less than  a  twofold increase in  the  CD8 + 
CD441o  population in both  groups and no  dramatic drop 
in CD8 +  CD441o  cells during the death phase.  The abso- 
lute number ofCD8 + CD441o cells remained two- to five- 
fold lower in -/-  compared with + / +  mice. 
Thus, in the absence of  B  cells and/or antibody, there is a 
higher rate of death  of activated CD8 +  cells and LCMV- 
specific CD8 + CTL memory cells after virus infection. The 
increased  cell death  results  in  lower  absolute  numbers  of 
activated CD8 +  cells and  LCMV-specific CTLp  in  -/- 
compared  with  +/+  mice.  Lower  numbers  of LCMV- 
specific CTL  in B  cell-deficient mice,  however,  was  not 
due to selective loss of CTL memory cells, since CTLp fre- 
quencies  in  the  spleens  of-/-  mice  were  comparable 
with that seen in  +/+  mice and remained relatively con- 
stant over time. 
Long-term  Protective  Immunity  in  B  Cell-deficient  Mice. 
LCMV-specific memory CTL are responsible for mediating 
protective immunity against reinfection  (13,  32).  As an in 
vivo test of CTL  memory, previously immunized B  cell- 
deficient mice  were  rechallenged with LCMV  Armstrong A 
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Figure  3.  Maintenance of CD8 +  CTL  memory  in B 
cell-deficient mice.  (-4) B  cell-deficient and  +/+  mice 
were infected with LCMV and the LCMV-specific CTLp 
frequency in the spleens was quantitated by limiting dilu- 
tion assay. In both groups,  CTLp frequencies  were main- 
tained at relatively the same rate over time, peaking at day 
8, showing a sigmficant decline by day  16, and stabilizing 
from  day  50  and beyond.  Expansion  of LCMV-specific 
CTL in the two groups was comparable,  with both B cell- 
deficient and  +/+  mice demonstrating up to a  10,000- 
fold increase in the number of LCMV-specific  CTL in the 
spleen by 8 d after infection. During the cell death phase, 
-/-  mice showed a greater decrease  in LCMV-specific 
CTL compared with +/+  mice.  Between days 8 and 50, 
there was a 60-fold drop in -/-  mice versus a 13-fold drop 
in  +/+  mice,  From  day  50  and  beyond,  both  groups 
maintained a  stable  population  of LCMV-specific  CTL, 
with absolute numbers in -/-  mice remaining lower than 
in +/+  mice. (B) By 8 d after infection, the total number 
of activated CD8 + T  cells increased 20-fold  in -/-  mice 
and 10-fold in +/+  mice. During the death phase,  -/- 
mice  showed greater loss of activated CD8 +  cells. Acti- 
vated CD8 + cells stabilized during the maintenance phase, 
returning close  to  preinfection levels  for both groups of 
mice.  (C)  In both -/-  and +/+  mice, the number of 
CD8 + CD441o  cells remained relatively stable throughout 
the time period studied,  although total numbers in -/- 
mice were two- to fivefold lower than in +/+  mice. 
and  evaluated  for  their  ability  to  generate  an  accelerated 
CTL  response. B  cell-deficient mice immunized  2  mo pre- 
viously were  re-chaUenged with  106  PFU  of LCMV  Arm- 
strong.  Naive  (previously uninfected)  age-matched B  cell- 
deficient  mice  were  similarly  infected  for  comparison. 
Direct ex vivo CTL  activity in the spleens was measured at 
days  3  and  5  after  challenge.  Previously  immunized  -/- 
mice  generated  an  accelerated  LCMV-specific  CTL  re- 
sponse in the spleen,  with virus-specific  CTL  activity  evi- 
dent by day 3  after challenge  (Fig.  4  A). Naive  -/-  mice 
showed no measurable LCMV-specific  CTL  activity at this 
time.  By day  5  after challenge,  virus-specific  CTL activity 
increased even further in the previously immunized  group, 
with  65%  LCMV-specific  target cell lysis  at the  50:1  E/T 
ratio  compared  with  15%  in  the  naive  mice  (data  not 
shown). 
Levels  of infectious virus were  measured  on  day  3  after 
challenge, In immunized -/-  mice, levels of infectious virus 
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Figure 4.  Immunized B cell-deficient mice show accelerated memory CTL responses in vivo upon rechallenge with LCMV. B cell-deficient mice im- 
munized 2 mo earlier were re-challenged with 10  6 PFU of LCMV Armstrong Naive (uninfected) B cell-deficient mice received the challenge dose for 
comparison. (A) Direct ex vivo CTL activi  W in the spleens 3 d after challenge. Percent specific killing of infected targets [(% SlCr-release from LCMV- 
infected targets) -  (% SlCr-release from uninfected targets)] is shown for the indicated E/T ratios. Previously immunized mice generated an accelerated 
LCMV-specific CTL effector response by day 3. Naive mice had no LCMu  response at this time. (B) Level of infectious virus in the serum and 
tissues of challenged mice. Naive mice had high levels of infectious virus in the serum and tissues, whereas levels were below detection in previously im- 
munized mice. Thus, B cell-deficient mice were able to generate a LCMV-specific CTL memory response in vivo al~er viral challenge that was capable 
of quickly controlling viral spread. Data represent the average of two mice per group. Lines on bar graph indicate range for each group. 
in the serum, liver, lung, LN, or spleen, were below detec- 
tion, whereas naive -/-  mice had high levels of infectious 
virus in both serum and tissues at this time (Fig. 4 B). Previ- 
ously immunized  +/+  mice also had no detectable infec- 
tious  virus in  the  serum  and  tissues,  whereas  naive  +/+ 
mice had high levels of infectious virus that were compara- 
ble with those in the naive  -/-  mice  (data not shown). 
Thus, previously immunized B  cell-deficient mice gener- 
ated an accelerated CTL response after LCMV Armstrong 
challenge  and  quickly  controlled  viral infection,  demon- 
strafing the presence of CTL memory in vivo. 
As a more stringent in vivo test of CTL memory, chal- 
lenge experiments were also performed using LCMV vari- 
ant clone 13 or 28b. Clones 13 and 28b are virulent strains 
of LCMV that establish persistent infections in naive adult 
mice characterized by low LCMV-specific CTL responses 
and high levels of infectious virus in several tissues  (26,  27). 
B cell-deficient mice immunized between 3 and 6 mo ear- 
her with  LCMV Armstrong were  challenged with  1.5  ￿ 
10  6  i.v.  PFU  of clone  13  or 28b.  Naive,  age-matched B 
cell-deficient mice were challenged for comparison. Mice 
were killed 7 d after infection and direct ex vivo CTL ac- 
tivity in  the  spleen  was  measured.  CTL  activity in  im- 
mune  -/-  mice was 10-30-fold higher than in the naive 
-/-  mice (Table 4).  In addition,  there were striking dif- 
ferences in levels of infectious virus in serum and tissues be- 
tween the two groups. Immune -/-  mice had undetectable 
levels  of infectious  virus in  the  serum,  brain,  liver,  lung, 
and  spleen.  In sharp  contrast,  naive  -/-  mice had  very 
high levels of infectious virus in serum and tissues.  There- 
fore, in two different types of challenge experiments (Ann- 
strong or clones  13/28  b),  B  cell-deficient mice demon- 
strated accelerated LCMV-specific CTL memory responses 
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in  vivo  that  resulted  in  faster  clearance  of virus.  Thus, 
CTL-mediated protective immunity does not wane  (for at 
least 6  too)  in  the  absence of B  cells  or antigen-antibody 
complexes. 
Discussion 
In this study we have examined the role of B cells in the 
generation  and maintenance  of CD8 +  CTL memory. To 
address this issue we compared CTL responses to LCMV in 
normal (+/+)  versus B  cell-deficient mice. The CTL re- 
sponse to acute LCMV infection can be broken down into 
three  distinct  phases.  (a)  The initial  phase  (days  3-8  after 
infection) is the phase of antigen-driven expansion of virus- 
specific CD8 + T  cells and the development of effector CTL 
(i.e.,  direct  ex vivo  killers).  Most  of the  viral  antigen  is 
cleared during this period.  (b)  This is followed by a death 
phase  (between  days  10  and  30  after  infection)  during 
which >95% of the vires-specific CTL die and the number 
of direct effector cells falls below the level of detection.  (c) 
The third phase is the memory phase  (>30  d  after infec- 
tion) and is characterized by a stable pool of memory CTL 
that persist for the hfe span of the animal. The role of  B cells 
in each of these three phases was analyzed. We found that 
B  cells were not required for the expansion and activation 
of virus-specific CTL but that  the  death  phase was more 
pronounced in B cell-deficient mice. A greater proportion 
of activated CD8 + T  cells  died in these mice, resulting in 
lower absolute numbers of  virus-specific CTL. However, the 
memory phase was not affected by the absence of B  cells, 
and a stable number of LCMV-specific memory CTL per- 
sisted in B cell-deficient mice. Upon reinfection, the B cell- 
deficient mice that had resolved an acute LCMV infection TaMe 4.  Long-term  Protective Immunity in B Cell-deficient Mice 
LCMV-specific CTL in spleen 
Percent specific SlCr-release from MC57 
(H-2  b) targets at indicated E/T ratio 
LCMV infected  Uninfected 
LCMV titer 
(Log~0 PFU/ml of serum or gm of tissue) 
Days after 
Group  infection  50:1  16.6:1  5.5:1  50:1  16.6:1  5.5:1  Serum  Brain  Liver  Lung  Spleen 
Immune Mice* 
Naive mice 
105  65  46  22  2  0  0  <1.7  <2,7  <2.7  <2.7  <2,7 
135  75  66  34  11  5  2  <1.7  <2.7  <2.7  <2.7  <2.7 
175  78  58  29  10  5  2  <1.7  <2.7  <2.7  <2.7  <2.7 
26  13  6  5  1  0  5,5  5.6  8.2  8.1  5.9 
11  6  2  2  0  0  4.3  4.1  7.5  7,9  7.1 
*6-8-wk-old B cell-deficient mice were infected with 2 ￿  10  s PFU of LCMV Armstrong. 105-175 d later, mice were challenged with 1.5  ￿  106 
PFU of LCMV clone 13 or 28b. 7 d after challenge, mice were killed and direct ex vivo CTL activity and virus titers were measured. Age-matched 
naive -/-  mice were  challenged for comparison. LCMV-specific serum antibody was below detection  in both immune  -/-  and naive -/- 
mice. Data represent the average of two to four mice per group. 
were  able to make accelerated CTL responses in vivo and 
eliminated  virus  more  efficiently than  naive  B  cell-defi- 
cient mice. Taken together, these results show that neither 
B  cells nor antigen-antibody complexes are essential for the 
maintenance ofCD8 + memory CTL. 
B  cells were not required for the priming and activation 
of virus-specific CTL  responses.  The  kinetics and magni- 
tude  of the  effector CTL  response,  as measured by direct 
killing of infected targets by ex vivo isolated splenocytes (or 
LN cells), were almost identical in B  cell-deficient and + / + 
mice. Also, the overall expansion of activated CD8 + T  cells 
was  not  affected by the  absence  of B  cells; in both  +/+ 
and B  cell-deficient mice there was over a  10-fold expan- 
sion of activated CD8 + T  cells and a "-'10,000-fold increase 
in  the  number  of LCMV-specific  CTL  during  the  first 
week after virus infection. In addition, we found that virus- 
specific  CTL  from  B  cell-deficient mice  recognized  the 
same LCMV epitopes as did CTL from +/+  mice, and the 
same  hierarchy for  the  three  CTL  epitopes  (NP  396  and 
GP 33  >GP  276)  was seen in both  +/+  and  -/-  mice. 
Taken together, these results show that B  cells are not in- 
volved in the priming of virgin CD8 §  T  cells. In the past, 
this  issue  has  been  somewhat  controversial,  and  in  some 
studies, B  cells were found to be essential for T  cell priming 
in  vivo  (33-36).  However,  several  other  studies  (37-40) 
have shown that B  cells are unable to activate naive T  cells 
and  a  recent  paper  (41)  has  shown  that  B  cell-deficient 
mice do not have any defects in making primary CD4 + or 
CD8 +  T  cell responses to  a variety of antigens.  Our find- 
ing,  along with  these  other  reports,  provides  strong  evi- 
dence that B  cells are not needed for activating T  cells. It is 
worth pointing out that  there was  massive expansion and 
activation of CD8 +  T  cells in B  cell-deficient mice  after 
LCMV  infection.  These  results show  that  not  only are B 
cells not required for antigen presentation to naive CD8 + 
T  cells, but that B  cells play a minimal to no role in provid- 
ing any necessary signals and/or cytokines for proliferation 
and differentiation ofCD8 + CTL. 
B  cell-deficient mice were able to ehminate LCMV and 
at 8 d after infection there was no detectable infectious virus 
in any of the tissues tested (spleen, liver, lung, blood, brain, 
or kidney). This provides formal proof that antibody does 
not play an essential role in resolving LCMV infection. Ear- 
lier  studies  have  shown  that  CD8 +  CTL  are  the  major 
players in controlling LCMV infection (5, 6, 25, 42-45). 
Although no differences were seen during the expansion 
phase of the CTL response between B cell-deficient and +/+ 
mice, we found that the death phase was more pronounced 
in  -/-  mice. Between days 8  and 50 there was a 60-fold 
drop in the number ofLCMV-specific CTL in B  cell-defi- 
cient mice  compared with  a  13-fold drop  in  +/+  mice. 
During this period the total number of activated CD8 + T 
cells also dropped substantially more in the B  cell-deficient 
compared with +/+  mice (23- versus 7-fold). The net re- 
sult of this increased T  cell death was a lower absolute num- 
ber ofLCMV-specific CTL in B  cell-deficient mice (4--20- 
fold lower). However, it is worth noting that the difference 
in  the  frequency  of LCMV-specific  CTL/spleen  cells  or 
CD8 + T  cells between the two groups of mice was much less 
(three- to fourfold), and in some experiments the frequency 
of virus-specific CTL  was  the  same  in  +/+  and  B  cell- 
deficient mice. Why was there more overall T  cell death in 
the absence of B  cells? Activated T  cells die by apoptosis and 
there is evidence implicating bothfas and TNF in this pro- 
cess (46, 47). It is currently not well understood what type 
of signals and cellular interactions can rescue activated T  cells 
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have shown that LPS or TGF-~I  can prevent apoptosis of 
activated T  cells (48, 49). Our results suggest that B cells might 
deliver signals for rescuing peripheral  T  cells from death. 
B  cells  express  a  variety of adhesion/costimulatory  mole- 
cules 037-1, B7-2, CD40, etc.) on their cell surface that are 
potential candidates for mediating interactions with activated 
T  cells  (50). Some of these interactions may be involved in 
preventing cell death in peripheral  T  cells.  In this context, 
it is worth noting that uninfected B cell-deficient mice have 
lower  numbers  of both  CD4  and  CD8 +  T  cells  in  their 
spleens  compared with  age-  and  sex-matched  +/'+  mice 
(an average of 5.5 ￿  106 CD4 + T  cells in -/-  mice versus 
1.8  ￿  107 in  +/+  mice;  4  X  106 CD8 + T  cells in  -/- 
mice versus 9.7  ￿  106 in +/+  mice). 
A question of substantial interest was determining if CD8 + 
T  cell memory would persist in the absence of B  cells.  The 
results of this study show that CTL memory, as assessed by 
frequency  of virus-specific  CTL  or protective  immunity, 
does not decline in the absence of  B cells.  The frequency of 
LCMV-specific CTL remained relatively constant in B cell- 
deficient  mice  over a  6-mo  period,  and  these  mice were 
able to make an accelerated CTL response in vivo upon re- 
challenge  with  virus.  This  accelerated  CTL  response  was 
able to confer protection against a virulent strain (clone 13 
or 28b) of LCMV. These LCMV variants cause a persistent 
infection in  naive  adult  mice but  are  cleared by immune 
mice. Ability to control LCMV clone 13 or 28b is a defini- 
tive in vivo marker for CTL memory, and immunized B cell- 
deficient  mice  were  able  to  eliminate  this  infection  effi- 
ciently. 
It has been proposed that B  cells sustain T  cell memory 
by picking up antigen-antibody complexes trapped on FDC, 
processing this trapped antigen, and then presenting it to T 
cells  (8,  20,  21).  Our results  show that this pathway does 
not play an essential role in sustaining CD8 §  T  cell mem- 
ory. Our studies also show that once a stable pool of mem- 
ory CTL has developed, these cells  do not require any sig- 
nals/help  from B  cells.  Taken together,  these results  show 
that  memory CD8 +  T  cells  require  neither  antigen-anti- 
body complexes nor B  cells for their survival.  It will be of 
interest  to  determine  if the  same  rules  apply  for mainte- 
nance of CD4 + T  cell memory. 
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